Bacterial Drug Articles & Analysis: Older
8 news found
Antibacterial Serum Preparation Bacterial infections remain a significant concern globally, and the emergence of antibiotic-resistant strains has heightened this challenge. ...
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces that its CEO, Pierre Belichard, will provide a company update (in person) at the Jefferies Healthcare Conference in New York City, US which will take place June 8-10, 2022. ...
ByEnterome
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces that it will present for the first time proof-of-concept data from clinical trials with EO2401, its first-in-class off-the-shelf OncoMimics™ cancer immunotherapy at ...
ByEnterome
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial effector-based drug discovery platform, announces that its CEO, Pierre Belichard, will present at the BMO Biopharma Spotlight Series conference on Immunology and Inflammation, which will take place virtually April 6, 2022. ...
ByEnterome
This has so far allowed the company to discover the first gut bacterial signature predictive of drug response of immuno-oncology checkpoint inhibitors which it is developing as a potentially transformational medicine to convert non-responding patients to responders. This collaboration is a further validation of the Company’s technology following a major ...
N8 Medical, a clinical-stage biopharmaceutical company focused on developing novel combination medical devices and antifungal and anti-bacterial therapeutics for the prevention and treatment of serious and life-threatening infections, announced today that it appointed David S. ...
After examining infections in nursing homes in the United States over a 5 year period, the study concluded that rates of a variety of infections are increasing, including those caused by multiple drug-resistant organisms (MDROs). The report showed an 18% increase in multiple drug-resistant bacterial infections and an 11% increase in ...
![Dow Honors Winners of Sustainability Innovation Student Challenge [#DowInvestorDay]](https://d32zuqhgcrpxli.cloudfront.net/eyJidWNrZXQiOiJlZS1maWxlcyIsImtleSI6ImZpbGVzLzM1NDA3L2ltYWdlcy8zNTQwN18wXzIwMjUwNjA3MTQzOTQ0MDMxMzIwOV80MDAuanBnIiwiZWRpdHMiOnsicmVzaXplIjp7ImZpdCI6ImNvbnRhaW4iLCJiYWNrZ3JvdW5kIjp7InIiOjI1NSwiZyI6MjU1LCJiIjoyNTUsImFscGhhIjoxfSwid2lkdGgiOjI0MCwiaGVpZ2h0IjoxNDV9fX0= "Dow Honors Winners of Sustainability Innovation Student Challenge [#DowInvestorDay]")
A project that aims to better understand how sustainable chemistry can be applied to modern medicine, using drug-resistant bacterial infections and Type II diabetes as the model for treatment. ...